Strand Life Sciences, a subsidiary of Reliance Industries Limited, on Friday announced the launch of its Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test. According to the company’s statement, this test detects circulating tumour DNA in blood samples of cancer patients to provide a comprehensive analysis of 74 clinically relevant genes, providing invaluable insights for cancer treatment.
“Leveraging its extensive experience of 24 years, with over 50,000 genetic tests conducted, Strand Life Sciences has developed the SA74 LB Test to deliver unparalleled accuracy and sensitivity. The test utilizes Unique Molecular Identifiers (UMIs) to ensure high-confidence detection of genetic variants, making it a reliable tool for identifying potential biomarkers and guiding treatment decisions. Strand’s CAP and NABL-accredited lab ensures rigorous quality standards and adherence to international best practices,” the company said in a statement.
Key features of the SA74 LB Test include:
- Actionable Insights: Covers genomic alterations in 74 clinically relevant genes associated with therapy selection for solid tumours recommended by FDA and NCCN guidelines
- HighReliability: Utilizes UMI-based library preparation,achieving high analytical Sensitivity
- Deep Coverage: Ensures pre-UMI coverage of >15,000x and post-UMI coverage of >2,000x to provide greater sensitivity and comprehensive analysis of genetic alterations.
- Minimally Invasive: Requires only a peripheral blood sample, making it a convenient and comfortable option for patients.
The SA74 LB Test offers several advantages over traditional tissue biopsy methods, the company claims. Its minimally invasive nature and ability to capture genetic variability across various tumour sites make it a valuable tool for clinicians and patients alike. Liquid biopsies are the only option when tumours are not accessible or the biopsy tissue available is insufficient or of poor quality. By providing timely and accurate information, the SA74 LB Test can help optimize treatment plans and improve patient outcomes, it added.
“We are thrilled to expand our Somatic Advantage portfolio with the introduction of the SA74-LB Test. This actionable liquid biopsy test aims to make genetic testing more accessible and beneficial to patients. Strand Life Sciences is committed to driving innovation in precision medicine and empowering healthcare professionals with the necessary tools to deliver personalized care. The launch of the SA74 LB Test is a testament to the company’s dedication to advancing cancer diagnostics and improving patient lives,” Dr. Ramesh Hariharan, CEO of Strand Life Sciences, said in a statement.